ReGenX Biosciences

Executive Summary

ReGenX Biosciences is a biotechnology company specializing in gene therapies for rare diseases, utilizing its proprietary NAV Technology Platform based on novel adeno-associated virus (AAV) vectors. Founded in 2009 and headquartered in Rockville, Maryland, the company focuses on targeted gene delivery to address unmet medical needs. Its pipeline includes both in-house and partnered programs, although specific clinical-stage assets are not publicly detailed. With a valuation of approximately $440 million and 51.6 million shares outstanding, ReGenX is positioned in the competitive gene therapy space, leveraging its differentiated AAV vector technology to potentially improve efficacy and safety profiles. The company operates at the intersection of biologics, drug delivery, RNA & gene therapy, and viral technology, benefiting from partnerships that may expand its reach. While no commercial products are approved to date, the NAV platform has been validated through collaborations, and upcoming data readouts could serve as critical value inflections. The company's progress hinges on successful clinical translations and regulatory milestones, which are typical for a development-stage biotech.

Upcoming Catalysts (preview)

• Q3 2026Phase 1/2 Data Readout for Lead Gene Therapy Candidate60% success
• Q4 2026FDA Orphan Drug Designation for a Pipeline Program70% success
• Q2 2026New Partnership or Licensing Deal for NAV Platform50% success